United Kingdom Visual Prosthesis Market Size & Outlook, 2025-2033
United Kingdom Visual Prosthesis Market Insights
- Reed Intelligence analysis indicates that the United Kingdom Visual Prosthesis Market size, valued at USD 18.66 Million in 2024, is expected to expand to USD 55.52 Million by 2033.
- The United Kingdom market is forecasted to expand at a CAGR of 12.66% spanning 2026–2033.
- Retina Implant Alpha AMS held the leading position among By Product Type segments in 2024, based on market size.
- Retina Implant Alpha AMS is projected to post the fastest growth rate, sustaining its position as the most attractive By Product Type segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, United Kingdom accounted for 5.57% of the global Visual Prosthesis Market size.
- By 2033, United States is expected to lead the global Visual Prosthesis Market in terms of market size.
- Within Europe, Germany is projected to dominate the regional Visual Prosthesis Market size by 2033.
- United Kingdom is identified as the fastest-growing market in Europe, anticipated to reach USD 54.56 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 18.66 Million |
| Market Size In 2033 | USD 55.52 Million |
| Largest segment | Retina Implant Alpha AMS |
| Units | Revenue in USD Million |
| CAGR | 12.66% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Indication |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Kingdom Visual Prosthesis Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina Implant Alpha AMS | XX.x | XX.x | XX.x | 7.76 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Implantable Miniature Telescope | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Argus II | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Visual Prosthesis Market By Indication 2025-2033 (USD Million)
| By Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age-Related Macular Degeneration (AMD) | XX.x | XX.x | XX.x | 8.83 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retinitis Pimentos (RP) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Retinal Degenerative Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Visual Prosthesis Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Speciality eye clinics | XX.x | XX.x | XX.x | 8.89 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye care centres | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
